Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jul 26;15:705618. doi: 10.3389/fncel.2021.705618

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Moraes, Boldrini, Dionete, Andrade, Longhini, Santos, Lima, Silva, Dias Carneiro, Quintiliano, Ferrari, Damasceno, Pradella, Farias, Tilbery, Domingues, Senne, Fernandes, von Glehn, Brandão, Stella and Santos.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Neurofilament L chain (NfL), soluble HLA-G (sHLA-G) and tolerogenic properties of plasmacytoid dendritic cells (pDCs) during Natalizumab. (A) NfL levels were measured in the cerebrospinal fluid and (B) sHLA-G levels were measured in the serum, both obtained from MS patients and healthy donors. (C) HLA-G⁺, (D) CD274⁺, (E) HLA-DR⁺, and (F) CCR7⁺ expressed by pDCs (BDCA-2⁺) from healthy donors, untreated and NTZ-treated MS patients were evaluated using flow cytometry analyses. Results are represented by mean and standard deviation.